Developing an analytical framework to depict disruptions in the pharmaceutical supply chain during Covid-19: A scoping review

The COVID-19 pandemic impacted the pharmaceutical supply chain (PSC) globally. As a result, consumers, pharmaceutical industries, and retailers have been facing supply chain disruptions since 2020. This paper aims to identify the causes and effects of PSC disruptions through a scoping review and propose an analytical framework for further study in Australia and overseas. This scoping review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Based on inclusion/exclusion criteria, 47 full articles were included in this review. Studies show significant disruptions to PSC where important contributing factors include: (i) reduction in product supply due to production disruptions and border closures, (ii) increased demand for healthcare products and, (iii) changes in consumers' purchasing behaviour. The study developed an analytical framework that can systematically be used to map PSC disruption in regional settings in Australia and overseas.